GTx, Inc. (GTXI) Hits New 1-Year High at $10.43
Shares of GTx, Inc. (NASDAQ:GTXI) reached a new 52-week high on Friday . The company traded as high as $10.43 and last traded at $10.30, with a volume of 63943 shares. The stock had previously closed at $8.64.
Separately, Stifel Nicolaus began coverage on shares of GTx in a report on Thursday. They set a “buy” rating for the company.
GTx (NASDAQ:GTXI) last issued its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.40) EPS for the quarter. research analysts predict that GTx, Inc. will post -1.35 earnings per share for the current fiscal year.
An institutional investor recently bought a new position in GTx stock. Bank of New York Mellon Corp acquired a new position in GTx, Inc. (NASDAQ:GTXI) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 23,355 shares of the biopharmaceutical company’s stock, valued at approximately $124,000. Bank of New York Mellon Corp owned 0.15% of GTx at the end of the most recent reporting period. 9.00% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “GTx, Inc. (GTXI) Hits New 1-Year High at $10.43” was published by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.watchlistnews.com/gtx-inc-gtxi-hits-new-1-year-high-at-10-43/1697720.html.
GTx Company Profile
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.